2022
Kidney-Targeted Renalase Agonist Prevents Cisplatin-Induced Chronic Kidney Disease by Inhibiting Regulated Necrosis and Inflammation
Guo X, Xu L, Velazquez H, Chen TM, Williams RM, Heller DA, Burtness B, Safirstein R, Desir GV. Kidney-Targeted Renalase Agonist Prevents Cisplatin-Induced Chronic Kidney Disease by Inhibiting Regulated Necrosis and Inflammation. Journal Of The American Society Of Nephrology 2022, 33: 342-356. PMID: 34921111, PMCID: PMC8819981, DOI: 10.1681/asn.2021040439.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SequenceAnimalsAntineoplastic AgentsCell LineCisplatinCreatinineDisease Models, AnimalGene ExpressionGlomerular Filtration RateHepatitis A Virus Cellular Receptor 1HumansKidneyMiceMice, Inbred C57BLMice, KnockoutMonoamine OxidaseNanocapsulesPeptidesRenal Insufficiency, ChronicConceptsRenal proximal tubulesSingle-cell RNA sequencing analysisMesoscale nanoparticlesFirst doseCisplatin chemotherapyProximal tubulesAgonist peptideInduced Chronic Kidney DiseaseGenetic deletionNeck squamous cell carcinomaRNA sequencing analysisCisplatin-induced AKIKidney-targeted deliveryChronic kidney diseaseDevelopment of CKDSquamous cell carcinomaAdministration of cisplatinPlasma renalaseAdvanced headCell carcinomaInflammatory cytokinesKidney diseasePlasma creatinineSystemic administrationRegulated necrosis
2019
Regulated necrosis and failed repair in cisplatin-induced chronic kidney disease
Landau SI, Guo X, Velazquez H, Torres R, Olson E, Garcia-Milian R, Moeckel GW, Desir GV, Safirstein R. Regulated necrosis and failed repair in cisplatin-induced chronic kidney disease. Kidney International 2019, 95: 797-814. PMID: 30904067, PMCID: PMC6543531, DOI: 10.1016/j.kint.2018.11.042.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseKidney diseaseKidney injuryCisplatin-induced chronic kidney diseaseCisplatin-induced acute kidney injuryToll-like receptor 2Regulated necrosis pathwaysReversible kidney injuryAcute kidney injuryChronic kidney injuryProximal tubular damageKidney injury markersDoses of cisplatinEvidence of fibrosisMechanisms of progressionEffective chemotherapeutic agentWestern blot analysisFirst doseInjury markersIntraperitoneal cisplatinSignificant nephrotoxicityTubular damageKidney functionSecond doseCisplatin administration
2015
Three-Dimensional Morphology by Multiphoton Microscopy with Clearing in a Model of Cisplatin-Induced CKD
Torres R, Velazquez H, Chang JJ, Levene MJ, Moeckel G, Desir GV, Safirstein R. Three-Dimensional Morphology by Multiphoton Microscopy with Clearing in a Model of Cisplatin-Induced CKD. Journal Of The American Society Of Nephrology 2015, 27: 1102-1112. PMID: 26303068, PMCID: PMC4814184, DOI: 10.1681/asn.2015010079.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCisplatinDisease Models, AnimalImaging, Three-DimensionalMiceMicroscopy, Fluorescence, MultiphotonRenal Insufficiency, ChronicConceptsAtubular glomeruliGlomerular capsuleRole of fibrosisModel of cisplatinNew mouse modelUseful morphologic informationMultiphoton microscopyTraditional histologic methodsRenal diseaseCisplatin therapyGlomerular volumePathologic changesRenal sectionsCKDMouse modelCisplatin effectCisplatin exposureImportant causeMild increaseCuboidal cellsHistologic methodsMorphologic informationFibrosisTherapyGlomeruli
2013
Renalase in hypertension and kidney disease
Desir GV, Peixoto AJ. Renalase in hypertension and kidney disease. Nephrology Dialysis Transplantation 2013, 29: 22-28. PMID: 24137013, DOI: 10.1093/ndt/gft083.Peer-Reviewed Original Research
2010
Renalase deficiency aggravates ischemic myocardial damage
Wu Y, Xu J, Velazquez H, Wang P, Li G, Liu D, Sampaio-Maia B, Quelhas-Santos J, Russell K, Russell R, Flavell RA, Pestana M, Giordano F, Desir GV. Renalase deficiency aggravates ischemic myocardial damage. Kidney International 2010, 79: 853-860. PMID: 21178975, DOI: 10.1038/ki.2010.488.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseWild-type miceRenalase deficiencyKnockout micePlasma blood urea nitrogenLevels of renalaseMild ventricular hypertrophyRenalase knockout mouseNormal systolic functionTraditional risk factorsPlasma catecholamine levelsIschemic myocardial damageBlood urea nitrogenCardiac complicationsCardiovascular complicationsSystolic functionVentricular hypertrophyCardioprotective effectsCatecholamine levelsKidney diseaseMyocardial damageMyocardial necrosisRecombinant renalaseRisk factorsCardiac ischemia
2008
Renalase deficiency in chronic kidney disease, and its contribution to hypertension and cardiovascular disease
Desir GV. Renalase deficiency in chronic kidney disease, and its contribution to hypertension and cardiovascular disease. Current Opinion In Nephrology & Hypertension 2008, 17: 181-185. PMID: 18277152, DOI: 10.1097/mnh.0b013e3282f521ba.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseKidney diseaseBlood pressureAnimal modelsCardiac functionEnd-stage renal diseaseRegulation of renalaseSalt-dependent hypertensionDevelopment of hypertensionSystolic blood pressurePlasma renalaseRenalase deficiencyCatecholamine administrationSympathetic toneRenal diseaseKidney functionSubtotal nephrectomyPlasma catecholaminesCardiovascular diseaseHypertensionLower plasmaRenalaseCatecholaminesDiseaseAbnormalities